Dr. Rekdal is co-founder of Lytix Biopharma and has extensive research background within tumor immunology, oncolytic peptides and their abilities to induce potent tumor specific immune responses. Dr. Rekdal commenced his PhD on cytokines and tumor immunology in 1996. His postdoctoral work was focusing on oncolytic peptides and their abilities to induce potent tumor specific immune responses. This research forms the basis of Lytix Biopharma’s oncolytic peptide platform. Dr. Rekdal is leading the collaboration with several distinguished researchers and institutions to further explore the unique ability of oncolytic peptides to reprogram non-inflamed or suppressive tumor microenvironment in experimental models and in cancer patients. He also serves as a visiting professor at the University of Tromsø, Norway.
Gjest Breistein, MSc, CFO
Mr. Breistein has eight years of experience from PwC as an auditor and consultant working with public and private companies across multiple industry sectors. Before joining Lytix Biopharma he was in PwC’s capital markets group advising clients in capital market transactions, financing and listing processes.
Mr. Breistein is a state authorized public accountant, and he holds a master in applied economics and finance from Copenhagen Business School and a master in professional accountancy from BI Norwegian School of Management.
Baldur Sveinbjørnsson, PhD, CSO
Baldur Sveinbjørnsson achieved a Dr. Philos degree at the Medical Faculty of University of Tromsø 1998 with a focus on mechanisms and mediators behind immunomodulation of experimental tumors. Since then, Dr. Sveinbjørnsson has gained a broad experience of preclinical oncology at University of Tromsø and Karolinska Institutet Stockholm.
Dr. Sveinbjørnsson has been involved in the research activities of Lytix Biopharma since the beginning and has the last years led the company research activities as Director Scientific Research. Dr. Sveinbjørnsson is also a visiting professor at the University of Tromsø.
Jørund Sollid, PhD, CLP, CBO
Dr. Sollid has for the last 12 years been working within business development, licensing and strategic partnership, both from the buy- and sell side for early stage and on-market assets. He has experience from the whole asset value chain, from basic research to pre-clinical stage, clinical progression and launching and selling products, and had roles both in medical department, commercial operations and traditional business development and licensing. Prior to joining Lytix he was Head of Business Development and Licensing in Mundipharma with global business segment responsibility. Sollid holds a PhD within physiology and is a certified licensing professional.